JPRN-UMIN000001090已完成3 期
Randomized Phase III Study of Adjuvant Endocrine-Therapy with or without Chemotherapy for Postmenopausal Breast Cancer Patients who Responded to Neoadjuvant Letrozole - N-SAS BC 06: New primary Endocrine-therapy Origination Study(NEOS)
EOS executive committee0 个研究点目标入组 850 人开始时间: 2008年3月20日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 850
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Positive sentinel lymph nodes before the registration. 2. Synchronous or asynchronous bilateral breast cancer. 3. Multifocal breast cancer of plural region 4. Double invasive carcinoma (in less than 5 years after the last treatment). 5. History of breast cancer. 6. Under treatment with continuous systemic steroid, estrogen or SERM. 7. Active participant in any other clinical trial for breast cancer. 8. Patient judged inappropriate for this study by the physicians.
研究者
相似试验
进行中（未招募）
1 期
A Study of Nivolumab in Combination with Ipilimumab Compared toNivolumab Alone in Treatment of Patients After Complete Resection ofStage IIIb/c/d or Stage IV Melanoma.Stage IIIb/c/d or Stage IV no evidence of disease (NED) melanomafollowing complete resection of the lesion(s) with high risk of relapse.MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 100000004864EUCTR2016-003729-41-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO1,844
进行中（未招募）
1 期
A Study of Nivolumab in Combination with Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.Stage IIIb/c/d or Stage IV no evidence of disease (NED) melanoma following complete resection of the lesion(s) with high risk of relapse.MedDRA version: 19.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 100000004864EUCTR2016-003729-41-ESBristol-Myers Squibb International Corporation1,125
进行中（未招募）
1 期
A Study of Nivolumab in Combination with Ipilimumab Compared to Nivolumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.EUCTR2016-003729-41-GBBristol-Myers Squibb International Corporation2,560
进行中（未招募）
1 期
A Study of Nivolumab in Combination with Ipilimumab Compared to Nivolumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.Stage IIIb/c/d or Stage IV no evidence of disease (NED) melanoma following complete resection of the lesion(s) with high risk of relapse.MedDRA version: 20.0Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 100000004864EUCTR2016-003729-41-BEBristol-Myers Squibb International Corporation2,560
进行中（未招募）
1 期
A Study of Nivolumab in Combination with Ipilimumab Compared to Nivolumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.EUCTR2016-003729-41-PLBristol-Myers Squibb International Corporation1,844